SAN DIEGO--(BUSINESS WIRE)--June 8, 2007--Illumina, Inc., (NASDAQ:ILMN) today announced that researchers from the California Institute of Technology and Stanford University School of Medicine, and the National Heart, Lung, and Blood Institute of the National Institutes of Health are the first in the industry to use the Solexa Sequencing technology with the Genome Analyzer to generate significant chromatin immunoprecipitation sequencing, or ChIP-Seq results within months of system installation, and have study findings accepted for publication by high-profile peer-reviewed journals. These studies appear in the June 8, 2007 edition of Science and the May 18, 2007 issue of Cell, respectively.
